The company will not receive any of the proceeds from the sale of the resale shares by the holder.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Agenus publishes C-800-01 trial data in The Journal for ImmunoTherapy of Cancer
- Agenus appoints Jose Iglesias as chief medical affairs officer
- Agenus Inc. Reports Q3 2025 Financial and Clinical Progress
- Promising Developments and Strategic Partnerships Justify Buy Rating for Agenus
- Agenus reports Q3 EPS $1.94, consensus $2.20